ArticleCureus2026
Association of Lithium Exposure With Alzheimer's Disease: A Propensity Score-Matched Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLithium has been widely studied for its potential neuroprotective effects through mechanisms implicated in Alzheimer's disease (AD), yet evidence from large real-world populations remains inconsistent. Clarifying the association between lithium exposure and AD risk in routine clinical practice is important given lithium's widespread use in mood disorders.
objectiveThis study aims to examine the association between lithium exposure and the incidence and time to diagnosis of AD among adults with bipolar disorder or recurrent major depressive disorder.
methodsWe conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Adults aged 50 years or older with bipolar disorder or recurrent major depressive disorder and no prior diagnosis of dementia or neurodegenerative disease were identified. Patients with documented lithium exposure for at least one year were propensity score-matched 1:1 to patients without lithium exposure on demographic and clinical covariates. Follow-up began one year after cohort entry. The primary outcome was incident AD, identified using the International Classification of Diseases, 10th Revision, code G30. Cumulative risk measures, Kaplan-Meier survival analysis, and Cox proportional hazards models were used to assess associations.
resultsThe matched cohorts included 67,020 patients each. Incident AD occurred in 34 patients in the lithium cohort and 69 patients in the no lithium cohort. Lithium exposure was associated with a lower recorded risk of AD, with a risk ratio of 0.49 (95% confidence interval (CI) = 0.33-0.74) and an odds ratio of 0.49 (95% CI = 0.33-0.74). Time-to-event analysis demonstrated a lower hazard of AD diagnosis among lithium-exposed patients (hazard ratio = 0.48; 95% CI = 0.32-0.73; log rank p < 0.001). Among patients who developed AD, the number of AD-coded encounters did not differ significantly between the cohorts.
conclusionIn this large real-world cohort of older adults with mood disorders, lithium exposure was associated with a lower recorded incidence and hazard of AD. Although absolute event rates were low, the consistency of findings across analytic approaches supports a potential protective association and highlights the need for prospective studies with detailed exposure and cognitive assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.